Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Author:

Powles Thomas1,O'Donnell Peter H.2,Massard Christophe3,Arkenau Hendrik-Tobias4,Friedlander Terence W.5,Hoimes Christopher J.6,Lee Jae Lyun7,Ong Michael8,Sridhar Srikala S.9,Vogelzang Nicholas J.10,Fishman Mayer N.11,Zhang Jingsong11,Srinivas Sandy12,Parikh Jigar13,Antal Joyce14,Jin Xiaoping14,Gupta Ashok K.14,Ben Yong15,Hahn Noah M.16

Affiliation:

1. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, England

2. Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, Illinois

3. Department of Cancer Medicine, Institut Gustave Roussy Cancer Centre, Villejuif, France

4. Drug Development Unit, Sarah Cannon Research Institute, University College London Cancer Centre, London, England

5. Division of Genitourinary Medical Oncology, University of California, San Francisco Medical Center

6. School of Medicine, Case Western Reserve University Seidman Cancer Center, Cleveland, Ohio

7. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

8. Department of Medicine, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

9. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

10. Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas

11. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida

12. Division of Medical Oncology, Stanford University, Stanford, California

13. Department of Medicine, Augusta University, Augusta, Georgia

14. Immuno-Oncology Clinical Development, MedImmune, Gaithersburg, Maryland

15. Immuno-Oncology Clinical Development, AstraZeneca, Gaithersburg, Maryland

16. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3